Location History:
- Maharastra, IN (2012)
- N. Mumbai, IN (2017)
- Navi Mumbai, IN (2014 - 2020)
Company Filing History:
Years Active: 2012-2020
Title: Inventor Sukumar Sinha: Innovator in Pharmaceutical Chemistry
Introduction
Sukumar Sinha, an accomplished inventor based in Navi Mumbai, India, has made significant contributions to the field of pharmaceutical chemistry. With a portfolio of 8 patents, he has demonstrated a commitment to innovation that addresses crucial needs in the medical and pharmaceutical industries.
Latest Patents
Among Sukumar Sinha's latest inventions are two noteworthy processes that have the potential to enhance drug production. The first is a **process for the preparation of deoxycholic acid**, which details a method involving the reaction of specific compounds to obtain deoxycholic acid or its salts. This invention not only outlines the steps for synthesis but also provides a purification method for the final product. His second recent patent focuses on the **process for the preparation of canagliflozin** and its intermediates, showcasing his innovative approach to improving the accessibility of important pharmaceutical compounds.
Career Highlights
Sukumar Sinha has had an impressive career, particularly with his tenure at Glenmark Pharmaceuticals Limited and Glenmark Generics Limited. His work in these companies has allowed him to develop and refine his inventions, which have the potential to impact patient care positively.
Collaborations
Throughout his career, Sukumar has collaborated with notable professionals in the field, including Mubeen Ahmed Khan and Shekhar Bhaskar Bhirud. These collaborations have likely contributed to the innovative ideas that have emerged through his patents.
Conclusion
Sukumar Sinha stands out as an influential figure in pharmaceutical innovation. His contributions in the form of patents reflect a dedication to improving medical treatments and highlight the importance of collaboration in advancing scientific knowledge. As he continues to work and innovate, his impact on the pharmaceutical industry is expected to grow even further.